Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ibuprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.70 |
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 0.70 |
| ▸ | CXCR1 | P25024 | 5/20 | 0.70 |
| ▸ | CXCR2 | P25025 | 5/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.70 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.70 |
| ▸ | ALB | P02768 | 1/20 | 0.70 |
| ▸ | ESR1 | P03372 | 1/20 | 0.70 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.70 |
| ▸ | RARB | P10826 | 1/20 | 0.70 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | HTR2A | P28223 | 1/20 | 0.70 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.70 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.70 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ibuprofen SCHEMBL8076351 | 1.00 | CXCR1 (0.70) | CXCR1CXCR2PTGS1PTGS2LMNA | |
| Ibuprofen SCHEMBL997451 | 0.98 | CXCR1 (0.68) | CXCR1CXCR2PTGS1PTGS2LMNA | |
| Ibuprofen SCHEMBL17373646 | 0.98 | CXCR1 (0.68) | CXCR1CXCR2PTGS1PTGS2LMNA | |
| Ibuprofen SCHEMBL139713 | 0.98 | CXCR1 (0.68) | CXCR1CXCR2PTGS1PTGS2LMNA | |
| Ibuprofen SCHEMBL8081018 | 0.98 | CXCR1 (0.68) | CXCR1CXCR2PTGS1PTGS2LMNA | |
| Ibuprofen SCHEMBL465258 | 0.96 | CXCR1 (0.70) | CXCR1CXCR2PTGS1PTGS2LMNA | |
| Ibuprofen SCHEMBL9321827 | 0.96 | CXCR1 (0.70) | CXCR1CXCR2PTGS1PTGS2LMNA | |
| Ibuprofen SCHEMBL30222251 | 0.96 | CXCR1 (0.70) | CXCR1CXCR2PTGS1PTGS2LMNA | |
| Ibuprofen SCHEMBL1179006 | 0.96 | CXCR1 (0.70) | CXCR1CXCR2PTGS1PTGS2LMNA | |
| Ibuprofen SCHEMBL1586498 | 0.96 | CXCR1 (0.70) | CXCR1CXCR2PTGS1PTGS2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1599 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12514833-B2 | Combination of ibuprofen and tramadol for relieving pain | FARMALÍDER, S.A. (ES) | 2026-01-06 | — | — | US | claimed |
| US-20250387343-A1 | Nanoparticle Compositions and Methods for Synthesis Thereof | ICEUTICA PTY LTD (AU) | 2025-12-25 | — | — | US | claimed |
| CN-120000579-A | External gel material for oral mucositis and preparation method thereof | 佳木斯大学 | 2025-05-16 | — | — | CN | claimed |
| CN-119792642-A | Nerve repair membrane and preparation method and application thereof | 宁波光远致信生物科技有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119656371-A | Polymer crosslinked self-curing drug-loaded bone cement and preparation method thereof | 湖北中部医疗科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| US-20250049674-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING AT LEAST A MEROCYANINE AND A HYDROTROPE | L'OREAL (FR) | 2025-02-13 | — | — | US | claimed |
| US-20240423888-A1 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION COMPRISING AT LEAST ONE MEROCYANINE AND AT LEAST ASCORBIC ACID AND/OR A DERIVATIVE THEREOF | L'OREAL (FR) | 2024-12-26 | — | — | US | claimed |
| CN-119015483-A | Liquid band-aid and preparation method and application method thereof | 宁波慈溪生物医学工程研究所 | 2024-11-26 | — | — | CN | claimed |
| CN-118871078-A | Cosmetic or dermatological composition comprising at least a merocyanine and a hydrotrope | 欧莱雅 | 2024-10-29 | — | — | CN | claimed |
| EP-4447895-A1 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION COMPRISING AT LEAST ONE MEROCYANINE AND AT LEAST ASCORBIC ACID AND/OR A DERIVATIVE THEREOF | L'OREAL (FR) | 2024-10-23 | — | — | EP | claimed |
| CN-1068734-A | THERAPEUTIC AGENT | BOOTS CO PLC (GB) | 1993-02-10 | — | — | CN | claimed |
| EP-0523847-A1 | Taste mask coating for preparation of chewable pharmaceutical tablets | McNEIL-PPC, INC. (US) | 1993-01-20 | — | — | EP | claimed |
| US-5180590-A | Mixture with sodium salt, sodium bicarbonate and citric acid | AESCULAPIUS-PHARMA S.A. (CH) | 1993-01-19 | — | — | US | claimed |
| EP-0346006-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING IBUPROFEN-CYCLODEXTRIN COMPLEXES | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1992-12-30 | — | — | EP | claimed |
| WO-1992020334-A1 | PHARMACEUTICAL COMPOSITION COMPRISING IBUPROFEN SALT | THE BOOTS COMPANY PLC (GB) | 1992-11-26 | — | — | WO | claimed |
| EP-0351353-B1 | ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITION WITH AN IBUPROFEN BASE, WITH ELIMINATION, IN SOLUTION, OF THE BITTER TASTE, BURNING IN THE THROAT AND INTESTINAL TOXICITY | ELAN CORPORATION, Plc (IE) | 1992-03-18 | — | — | EP | claimed |
| US-5019563-A | Pharmaceutical composition | RECKITT & COLMAN PRODUCTS LIMITED (GB) | 1991-05-28 | — | — | US | claimed |
| EP-0351353-A1 | Anti-inflammatory pharmaceutical composition with an ibuprofen base, with elimination, in solution, of the bitter taste, burning in the throat and intestinal toxicity | ELAN CORPORATION, Plc (IE) | 1990-01-17 | — | — | EP | claimed |
| EP-0346006-A1 | Pharmaceutical compositions containing ibuprofen-cyclodextrin complexes | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1989-12-13 | — | — | EP | claimed |
| US-3987094-A | PREPARING CARBOXYLIC ACIDS FROM GLYCIDONITRILES | THE UPJOHN COMPANY (US) | 1976-10-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387343-A1 | Nanoparticle Compositions and Methods for Synthesis Thereof | SAMM50, SI, TNNC1 | PTGS1 3755/4885PTGS2 4273/4885CXCR1 4379/4885 |
| US-20240423888-A1 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION COMPRISING AT LEAST ONE MEROCYANINE AND AT LEAST ASCORBIC ACID AND/OR A DERIVATIVE THEREOF | KRT18, PROC, DSC1 | PTGS1 3581/4885PTGS2 4078/4885CXCR1 2108/4885 |
| US-20250049674-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING AT LEAST A MEROCYANINE AND A HYDROTROPE | NAPRT, NAMPT, NNMT | PTGS1 78/4885PTGS2 149/4885CXCR1 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.